CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0302

Primobolan E Raw

Filed under Raw Materials. The bureau holds 140 laboratory returns for this compound from 43 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

43 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 7 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
WuXi TIDESCASE #VI-2026-0335 A 5 10.0 9.9 10.0 27 Dec 2025 21 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 4 10.0 10.0 10.0 16 Dec 2025 15 Jul 2026
AmbioPharmCASE #VI-2026-0177 A 4 10.0 10.0 10.0 8 May 2026 1 Aug 2026
JEEP PeptidesCASE #VI-2026-0457 A 3 10.0 9.9 10.0 14 Jan 2026 23 May 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 10.0 9.9 10.0 24 May 2026 11 Jul 2026
GenScript PeptidesCASE #VI-2026-0860 A 3 10.0 9.9 10.0 20 Mar 2026 26 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 2 10.0 10.0 10.0 7 Jul 2026 17 Aug 2026
AsymchemCASE #VI-2026-0091 A 2 10.0 10.0 10.0 20 Dec 2025 28 Jul 2026
HomopeptideCASE #VI-2026-0760 A 5 9.9 9.9 10.0 23 May 2026 23 May 2026
Kerui PeptidesCASE #VI-2026-0626 A 4 9.9 9.9 10.0 6 May 2026 16 Jun 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 3 9.9 9.9 10.0 14 Jan 2026 3 Jul 2026
QYAOBIOCASE #VI-2026-0861 A 3 9.9 9.9 10.0 10 Jan 2026 3 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 3 9.9 9.9 10.0 16 Feb 2026 7 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 3 9.9 9.9 10.0 23 Mar 2026 2 Jun 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 9.9 9.9 9.9 8 Mar 2026 25 Jul 2026
Sangon BioCASE #VI-2026-0671 A 2 9.9 9.9 10.0 3 Jul 2026 6 Jul 2026
BachemCASE #VI-2026-0314 A 2 9.9 9.9 10.0 1 May 2026 14 May 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 10.0 20 Feb 2026 9 Jul 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 2 9.9 9.9 10.0 4 Nov 2025 28 Feb 2026
Sigma-AldrichCASE #VI-2026-0829 A 2 9.9 9.9 10.0 23 Apr 2026 13 May 2026
PolyPeptide GroupCASE #VI-2026-0143 A 2 9.9 9.9 10.0 8 Dec 2025 28 May 2026
SinoPepCASE #VI-2026-0387 A 2 9.9 9.9 9.9 9 Mar 2026 24 Apr 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 5 9.4 8.3 10.0 21 May 2026 21 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 3 8.8 8.2 10.0 21 May 2026 21 May 2026
Top PeptideCASE #VI-2026-0721 X 2 8.8 8.5 9.0 17 Dec 2024 25 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 5 8.7 8.0 10.0 24 May 2026 24 May 2026
UtherCASE #VI-2026-0902 X 1 8.7 8.7 8.7 20 Jun 2025 20 Jun 2025
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 8 8.6 6.5 10.0 21 May 2026 21 May 2026
Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 X 1 8.2 8.2 8.2 24 Apr 2025 24 Apr 2025
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 3 8.0 7.5 8.3 21 May 2026 21 May 2026
Yiwu Aozuo Trading CoCASE #VI-2026-0798 X 5 7.9 6.1 9.4 13 Jun 2025 20 May 2026
Qing Li PeptideCASE #VI-2026-0469 X 14 7.4 5.5 9.1 20 Jun 2025 25 May 2026
Eternal PeptidesCASE #VI-2026-0842 X 2 7.3 7.0 7.7 6 May 2025 21 May 2026
Atomik LabzCASE #VI-2026-0327 X 3 6.9 5.5 8.4 27 Feb 2025 17 May 2026
Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 X 1 6.9 6.9 6.9 25 Apr 2025 25 Apr 2025
Alpha-GenCASE #VI-2026-0905 X 2 6.8 5.1 8.5 20 Jun 2025 25 May 2026
HazelCASE #VI-2026-0392 X 1 6.7 6.7 6.7 27 Feb 2025 27 Feb 2025
Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 E 3 6.2 4.0 8.1 3 Jul 2025 23 May 2026
Royal PeptidesCASE #VI-2026-0264 X 3 6.1 4.8 6.9 2 Jul 2025 26 Jan 2026
SRY LabsCASE #VI-2026-0657 X 4 5.3 3.7 6.3 13 Feb 2025 20 May 2026
Limitless Life NootropicsCASE #VI-2026-0980 X 2 4.5 2.8 6.3 27 Feb 2025 25 May 2026
PurePEPSCASE #VI-2026-0552 X 1 3.8 3.8 3.8 25 Apr 2025 25 Apr 2025

Open any subject to view the batch-level evidence for Primobolan E Raw alone.